You have accessJournal of UrologyHealth Services Research: Quality Improvement & Patient Safety III (PD38)1 Sep 2021PD38-09 FACTORS ASSOCIATED WITH PALLIATIVE CARE UTILIZATION IN ADVANCED AND METASTATIC RENAL CELL CARCINOMA Hiren Patel, Sinae Kim, Arnav Srivastava, Brian Shinder, Joshua Sterling, Biren Saraiya, Tina Mayer, Isaac Kim, Saum Ghodoussipour, Thomas Jang, and Eric Singer Hiren PatelHiren Patel More articles by this author , Sinae KimSinae Kim More articles by this author , Arnav SrivastavaArnav Srivastava More articles by this author , Brian ShinderBrian Shinder More articles by this author , Joshua SterlingJoshua Sterling More articles by this author , Biren SaraiyaBiren Saraiya More articles by this author , Tina MayerTina Mayer More articles by this author , Isaac KimIsaac Kim More articles by this author , Saum GhodoussipourSaum Ghodoussipour More articles by this author , Thomas JangThomas Jang More articles by this author , and Eric SingerEric Singer More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002048.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Palliative care (PC) offers various benefits for patient with cancer that include, but are not limited to, decrease in disease-specific symptoms and improvement in functional status. Several oncological guidelines have adopted early integration of PC into oncologic care to improve quality of life among patients with advanced malignancies. However, PC utilization patterns and factors associated with its use in advanced renal cell carcinoma (RCC) remain poorly understood. METHODS: Using the National Cancer Database (NCDB), we abstracted patients with Stage III and IV RCC from 2004-2014 and evaluated PC utilization amongst this cohort. Socioeconomic and clinical factors were compared for patient receiving and not receiving PC for advanced RCC. Multivariable logistic regression identified factors that were associated with receipt of PC among the overall cohort and treatment-based cohorts. RESULTS: Among 20,122 and 42,014 patients with Stage III and IV RCC, 329 and 9,317 patients received PC, respectively. From 2004 to 2014, PC utilization was stable at ∼1% for Stage III RCC and minimally increased from 17% to 20% for Stage IV RCC. Multivariable analysis demonstrated that increased comorbidities, insurance status, higher education status, facility location, care at a comprehensive cancer program or integrated network, sarcomatoid histology, and prior treatments significantly increased likelihood of palliative care utilization. We uncover socioeconomic and clinical factors that are associated with receipt of palliative care use in a treatment-specific manner. CONCLUSIONS: While PC utilization has minimally increased for Stage IV RCC, there are several demographic, socioeconomic, and clinical factors that predict PC use, especially in a treatment-specific manner, among patients with advanced RCC. Taken together, this suggests the need for more equitable and systematic use of PC among patients with advanced RCC. Source of Funding: This work is supported by a grant from the National Cancer Institute (P30CA072720) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e665-e666 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiren Patel More articles by this author Sinae Kim More articles by this author Arnav Srivastava More articles by this author Brian Shinder More articles by this author Joshua Sterling More articles by this author Biren Saraiya More articles by this author Tina Mayer More articles by this author Isaac Kim More articles by this author Saum Ghodoussipour More articles by this author Thomas Jang More articles by this author Eric Singer More articles by this author Expand All Advertisement Loading ...